this article talks about people who have a lot of money to invest. these people are buying and selling things called "options" for a company named pfizer. options are like a special ticket that lets people make more money if the company does well. but it can also make people lose money if the company does not do well. the article says that these big money people are split between being positive or negative about pfizer. they have different plans for how much they want the company's stock to be worth. it's like when you and your friends have different ideas about how to play a game, so you all decide to do different things. Read from source...

1. The article's title suggests whales, specifically large institutional investors, are doing something noteworthy with Pfizer (PFE). Yet, it doesn't provide a clear or definitive answer as to what this action is, just that it's "something." This lack of specificity could lead to confusion and misinterpretation by readers.

2. The article points out that while the overall sentiment of big-money traders is split between 77% bullish and 22% bearish, it doesn't delve into reasons or data to support these percentages. This leaves readers with unanswered questions about why these percentages were chosen.

3. In the section "What's The Price Target?" the article states that significant investors are aiming for a price territory stretching from $29.0 to $80.0 for Pfizer over the recent three months. However, it doesn't provide any evidence or reasoning to support this claim, making this statement appear arbitrary.

4. The chart in the article called "Pfizer Option Activity Analysis: Last 30 Days" is difficult to read and interpret due to its size and black and white color scheme. It could be improved by making it more visually appealing and easier to understand, which would benefit readers who rely on visual aids for comprehension.

5. The section "What The Experts Say On Pfizer" repeats similar information in different sentences, which can confuse readers. For example, the text says "An analyst from Cantor Fitzgerald downgraded its action to Overweight with a price target of $45." and later "In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45." The first statement is repeated almost verbatim, creating redundancy.

6. Lastly, the article ends with a plug for Benzinga Pro, which could be seen as intrusive and not in the best interest of the reader. It undermines the credibility of the article by coming across as a sales pitch rather than objective journalism.

Overall, while the article touches upon interesting topics such as options trading and Pfizer's market position, it could greatly benefit from increased clarity, specificity, and evidence-based reasoning. It lacks depth and thorough analysis, which could leave readers feeling uninformed or misled.

Based on the article "Check Out What Whales Are Doing With PFE", it is recommended to consider investing in Pfizer (PFE) due to the bullish stance taken by big-money investors. These investors have made significant trades, indicating that they believe the price of PFE will rise within the next three months, with a potential price range from $29.0 to $80.0. The overall sentiment of these traders is split between 77% bullish and 22% bearish. Investors should note that options trading can be riskier than traditional stock trading, but it also has higher profit potential. As a result, managing this risk is crucial, and this can be achieved by staying updated on the latest options trades for PFE and closely following market indicators.